2015 Bio Investor Forum

ROTH Capital Partners and the Bio Industry Organization invite you to attend the
14th Annual Bio Investor Forum October 20-21, 2015 in San Francisco, CA.

Parc 55 San Francisco
55 Cyril Magnin Street
San Francisco, California, 94102

October 20-21, 2015

What is the BIO Investor Forum?

The BIO Investor Forum is an international biotech investor conference focused on early and established private companies as well as emerging public companies. The event features plenary sessions, business roundtables and therapeutic workshops, company presentations, and One-on-One PartneringTM meetings.

Why Attend the BIO Investor Forum?

  • Independent Host: One of the only independent investor conferences dedicated to helping early-stage biotech companies find sources of capital.

  • Efficient Partnering: Ideal venue for investors and company executives to discuss financial and strategic business issues affecting investment in biotech companies and explore potential partnerships and business collaborations to fuel research and development for promising innovation.

  • Global Scope: Attracts healthcare venture capital and public market investors and research analysts as well as business development executives from leading global pharmaceutical and biotechnology companies.

  • Compelling Voices: Offers ample networking opportunities, informative therapeutic and business workshops, and presentations from up-and-coming companies.

ROTH Capital Partners Logo


Bio Investor Participating Investors

Bio Investor Participating Companies

Bio Investor Forum BrochureBio Investor Forum

Qualifying investors can attend the BIO Investor Forum free of charge.  The requirements for a qualifying investor are below. Qualified investors: CLICK HERE to register.

Qualified investors are defined as institutional, private equity, angel and venture investors with funds on-hand, whose primary activity is direct investment in research and development companies (e.g., hedge fund, mutual fund, or venture fund). Equity research analysts from investment banking institutions and buy-side analysts also qualify as investors.

John Chambers | ROTH Capital Partners

ROTH Capital Partners Logo

John Chambers, Vice-Chairman and Head of Healthcare Investment Banking for ROTH Capital Partners, has been selected to the Bio Investor Forum Advisory Committee and will be Panelist for the "Status of the IPO Appetite, M&A, Foreign Shocks, and Higher Interest Rates?" (Information Below)

Business Panel Topic
Market Outlook | Status of the IPO Appetite, M&A, Foreign Shocks, and Higher Interest Rates?
Wednesday | October 21, 4:30 pm – 5:30 pm

While the appetite for new IPOs remains strong and cash is still flowing freely in the capital intensive biotech sector, concerns over valuation have the public markets on high alert. Investment banks are competing for the next biggest IPO with less clinical evidence in place up front. As M&A among payers and among biopharmas start a new round of consolidation, what does all this mean for privately held companies? Global economic factors have had a serious impact across all sectors, but how will biotech be affected? Has the biotech sector’s resilience strengthened since the last downturn?

This panel of diverse experts will discuss what we can learn from history and where the market is crossing a new frontier.


Brian Hagerty, Senior Director, Capital Markets, New York Stock Exchange


John Chambers, Vice-Chairman and Head of Healthcare Investment Banking, ROTH Capital Partners

Margarita Chavez, Director, Venture & Early Stage Collaborations, AbbVie Biotech Ventures

Asthika Goonewardene, Senior Biotech Analyst, Bloomberg Intelligence

David Woodhouse, PhD, Chief Financial Officer, NGM Biopharmaceuticals

Host Sponsor

Bio Industry Organization Logo

ROTH Capital Partners Logo

ROTH Capital Partners
888 San Clemente Dr. | Newport Beach, CA 92660 | (800) 678.9147 | roth.com | Member SIPC / FINRA